Cancer immunotherapy
A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.
1. A method for stimulating an immune response against IL-13Rα2 in a subject having tumor cells expressing IL-13Rα2, the method comprising the steps of:
(a) formulating an anti-cancer vaccine outside of the subject, the vaccine comprising an agent that can stimulate an immune response against IL-13Rα2 when administered to an animal, wherein the agent that can stimulate an immune response against IL-13Rα2 is a protein comprising the amino acid sequence of SEQ ID NO:1 or a protein fragment thereof; and (b) administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 and inhibit growth of the tumor cells in the subject; and (c) measuring stimulation of the immune response against IL-13Rα2 in the subject having tumor cells expressing IL-13Rα2.
2. The method of claim 1 , wherein the agent that can stimulate an immune response against IL-13Rα2 comprises a peptide comprising amino acids 27-343 of SEQ ID NO:1.
3. The method of claim 1 , wherein administering the vaccine to the subject stimulates an antibody response against IL-13Rα2.
4. The method claim 1 , wherein the vaccine further comprises an adjuvant.
5. The method of claim 4 , wherein the adjuvant comprises a substance selected from the group consisting of: an aluminum salt; an oil-in-water emulsion; a composition comprising saponin; a composition comprising a bacterial protein; and a cytokine.
6. The method of claim 4 , wherein step (b) of administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject comprises administering the vaccine in at least a first close and a second dose, wherein said first dose is administered to the subject at least 24 hours before said second dose is administered to the subject.
7. The method of claim 1 , wherein the cells expressing IL-13Rα2 are glioma cells.